{"brief_title": "Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "brief_summary": "The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.", "condition": "Non Small Cell Lung Carcinoma", "intervention_type": "Drug", "intervention_name": "gefitinib (Iressa)", "criteria": "Inclusion Criteria: - Clinical diagnosis of non-small cell lung cancer - Non-small cell lung cancer that is not curable with surgery, radiation, or combined modality chemoradiation - Failed two prior chemotherapy regimens which must have included platinum - Measurable disease Exclusion Criteria: - Treatment with more than two prior chemotherapy regimens - History of bone marrow transplantation or stem cell support - Pregnant or lactating women - Known history of prior gefitinib therapy - Known history of prior TLK286 therapy", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00080340.xml"}